Baird raised the firm’s price target on Medpace to $469 from $456 and keeps an Outperform rating on the shares. The firm said they continue to expect ~15% CDO revenue growth in 2024 and see potential for further EPS gains on strong interest income and operating efficiency.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MEDP: